EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT · NASDAQ Global Market
+$0.26 today
Vol 1.24M · Avg 0.95M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-75.8%
avg -170.5%
ROIC
-74.5%
avg -51.9%
ROA
-63.7%
avg -49.3%
Analysis
ROA is currently the strongest return metric at -63.7% versus its period average of -49.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jay S. Duker | President, Chief Executive Officer & Director | $1.35M | — | 67 | $177,431.00 | 0.21% |
George O. Elston | Executive Vice President & Chief Financial Officer | $904,802.00 | — | 61 | $91,691.00 | 0.11% |
Ramiro Ribeiro | Chief Medical Officer | $888,556.00 | — | 43 | $0.00 | <0.01% |
David Scott Jones | Senior Vice President | $672,084.00 | — | 58 | $6,950.00 | <0.01% |
Anna Kluczewska | Chief Executive Officer of AION Diagnostics Ltd, President of AION Diagnostics Ltd and Director of AION Diagnostics Ltd | $183,639.00 | — | — | — | — |
Michael Campbell | Chief Commercial Officer | — | — | — | $30,570.00 | 0.04% |
Marcia Sellos-Moura | Chief Scientific Officer | — | — | — | — | — |
Michael J. Maciocio | Chief Manufacturing Officer | — | — | — | $40,000.00 | 0.05% |
Ron I. Honig | Chief Legal Officer & Company Secretary | — | — | — | — | — |
Isabelle Lefebvre | Chief Regulatory Officer | — | — | — | — | — |
Jennifer Leonard | Chief People Officer & Senior Vice President of IT | — | — | — | $92,005.00 | 0.11% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$19,723.80
Sells
9
$1.97M
Net Sentiment
$1.95M
Net selling
Most Active
Ribeiro Ramiro
5 transactions
Analysis
Insiders reported 1 buys worth $19,723.80 and 9 sells worth $1.97M over the last 12 months. That adds up to net selling of $1.95M. Ribeiro Ramiro was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +1.3% (15yr)5 analysts |
| Revenue | N/A | N/A | +96.0% | +26.1% (15yr)4 analysts |
| Net Income | N/A | N/A | N/A | +25.2% (15yr)4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Recent growth has been strongest in Revenue at +96.0% over three years. Forward estimates point to Revenue at +26.1% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.55B
Kodiak Sciences Inc.
NASDAQ:KOD
$1.87B
Septerna, Inc.
NASDAQ:SEPN
$1.57B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.49B
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
$1.25B
Savara Inc.
NASDAQ:SVRA
$1.11B
Kura Oncology, Inc.
NASDAQ:KURA
$854.90M
Prime Medicine, Inc.
NASDAQ:PRME
$562.62M
Rezolute, Inc.
NASDAQ:RZLT
$487.72M
ProKidney Corp.
NASDAQ:PROK
$261.50M
Who manages EYPT?
EyePoint Pharmaceuticals, Inc. (EYPT) lists 11 active executives. The top listed executive is Anna Kluczewska, Chief Executive Officer of AION Diagnostics Ltd, President of AION Diagnostics Ltd and Director of AION Diagnostics Ltd.
Are EYPT insiders buying or selling?
Recent insider activity shows net buying of $44.53M.
Explore More
Continue the stock analysis
Jump to another research area for this company.